Zeba Sultana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zeba Sultana has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ansu Kumar
Cellworks Research India Ltd., Bangalore, India
2 shared publications - Shireen Vali
Cellworks Group, Inc., San Jose, CA, USA
2 shared publications - Taher Abbasi
Cellworks Group, Inc., San Jose, CA, USA
2 shared publications - Amitabha Mazumder
New York University Cancer Center, New York, NY, USA.
1 shared publication - Anay A Talawdekar
Cellworks Research India Pvt. Ltd, Bangalore, India.
1 shared publication - Anuj Tyagi
Cellworks Research India Pvt. Ltd, Bangalore, India.
1 shared publication
Latest Publications
- Open Access
- 1 February 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 43-14
Personalization of cancer treatment using predictive simulation
The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm. This move has spawned increased use of next generation sequencing to understand mutations and copy number aberrations in cancer cells. Initial personalization successes have been primarily driven by drugs targeting one patient-specific oncogene (e.g., Gleevec, Xalkori, Herceptin). Unfortunately, most cancers include a multitude of aberrations, and the overall impact on cancer signaling and metabolic networks cannot be easily nullified by a single drug. We used a novel predictive simulation approach to create an avatar of patient cancer cells using point mutations and copy number aberration data. Simulation avatars of myeloma patients were functionally screened using various molecularly targeted drugs both individually and in combination to identify drugs that are efficacious and synergistic. Repurposing of drugs that are FDA-approved or under clinical study with validated clinical safety and pharmacokinetic data can provide a rapid translational path to the clinic. High-risk multiple myeloma patients were modeled, and the simulation predictions were assessed ex vivo using patient cells. Here, we present an approach to address the key challenge of interpreting patient profiling genomic signatures into actionable clinical insights to make the personalization of cancer therapy a practical reality. Through the rational design of personalized treatments, our approach also targets multiple patient-relevant pathways to address the emergence of single therapy resistance. Our predictive platform identified drug regimens for four high-risk multiple myeloma patients. The predicted regimes were found to be effective in ex vivo analyses using patient cells. These multiple validations confirm this approach and methodology for the use of big data to create personalized therapeutics using predictive simulation approaches.
- 1 February 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 43-14
Open AccessPersonalization of cancer treatment using predictive simulation
The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm. This move has spawned increased use of next generation sequencing to understand mutations and copy number aberrations in cancer cells. Initial personalization successes have been primarily driven by drugs targeting one patient-specific oncogene (e.g., Gleevec, Xalkori, Herceptin). Unfortunately, most cancers include a multitude of aberrations, and the overall impact on cancer signaling and metabolic networks cannot be easily nullified by a single drug. We used a novel predictive simulation approach to create an avatar of patient cancer cells using point mutations and copy number aberration data. Simulation avatars of myeloma patients were functionally screened using various molecularly targeted drugs both individually and in combination to identify drugs that are efficacious and synergistic. Repurposing of drugs that are FDA-approved or under clinical study with validated clinical safety and pharmacokinetic data can provide a rapid translational path to the clinic. High-risk multiple myeloma patients were modeled, and the simulation predictions were assessed ex vivo using patient cells. Here, we present an approach to address the key challenge of interpreting patient profiling genomic signatures into actionable clinical insights to make the personalization of cancer therapy a practical reality. Through the rational design of personalized treatments, our approach also targets multiple patient-relevant pathways to address the emergence of single therapy resistance. Our predictive platform identified drug regimens for four high-risk multiple myeloma patients. The predicted regimes were found to be effective in ex vivo analyses using patient cells. These multiple validations confirm this approach and methodology for the use of big data to create personalized therapeutics using predictive simulation approaches.
- Open Access
- 21 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 128
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast genomic and proteomic data can be addressed by a comprehensive systems modeling approach.
- 21 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 128
Open AccessIn silico modeling predicts drug sensitivity of patient-derived cancer cells
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast genomic and proteomic data can be addressed by a comprehensive systems modeling approach.